openPR Logo
Press release

Hemophilia B Pipeline Drugs Report 2025: Exploring Emerging Therapies and Innovative Drug Developments Across Key Indications

10-08-2025 08:18 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Hemophilia B Pipeline Drugs Report 2025: Exploring Emerging

DelveInsight's, "Hemophilia B Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Hemophilia B pipeline landscape. It covers the Hemophilia B Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia B Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Hemophilia B Pipeline? Click here to explore the therapies and trials making headlines @ Hemophilia B Pipeline Outlook Report [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Hemophilia B Pipeline Report

* On 06 October 2025, Bayer announced a Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A
* DelveInsight's Hemophilia B Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hemophilia B treatment.
* The leading Hemophilia B Companies such as Shanghai Vitalgen BioPharma, Belief BioMed, TiumBio, Jiangsu Gensciences, Centessa Pharmaceuticals, Takeda, Sanofi, GC Biopharma Corp, Equilibra Bioscience LLC, Regeneron Pharmaceuticals, ISU Abxis and others.
* Promising Hemophilia B Therapies such as REGV131, LNP1265, APVO101, SPK-9001, ANB-002, Benefix, IB1001, marstacimab and others.

Want to know which companies are leading innovation in Hemophilia B? Dive into the full pipeline insights @ Hemophilia B Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Hemophilia B Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hemophilia B Pipeline Report also highlights the unmet needs with respect to the Hemophilia B.

Hemophilia B Overview

Hemophilia B is a rare genetic bleeding disorder characterized by a deficiency in factor IX clotting activity, leading to prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing. The age of diagnosis and frequency of bleeding episodes are related to the level of factor IX clotting activity. In severe cases, individuals may experience frequent spontaneous bleeding episodes, including joint or muscle bleeds, while those with moderate hemophilia B may have less frequent bleeding, typically after minor trauma. Individuals with mild hemophilia B usually do not have spontaneous bleeding episodes but may experience abnormal bleeding during surgery or tooth extractions. The severity of the condition and the frequency of bleeding episodes vary based on the level of factor IX activity, with severe cases usually diagnosed in early childhood and milder cases potentially not being diagnosed until later in life.

Hemophilia B Emerging Drugs Profile

* BBM-H901: Belief Biomed

BBM-H901 is indicated for prophylactic treatment of bleeding in adults with hemophilia B. BBM-H901 is designed to restore the production of factor IX (FIX) the blood-clotting protein that is faulty or missing in people with hemophilia B by delivering a functional copy of the F9 gene to liver cells, which are the main producers of clotting factors in the body. Gene therapy components are delivered to liver cells by a modified, harmless adeno-associated virus (AAV) that works as a vehicle. The gene therapy is given as a single intravenous (into-the-vein) infusion. The drug BBM-H901 is in the Phase III clinical trial for the treatment of hemophilia B.

* ISU304: ISU ABXIS

ISU304 (Dalcinonacog alfa, DalcA) is a modified recombinant Factor IX protein for the prophylactic therapy of patients with Hemophilia B which is caused by a deficiency of coagulation FIX. It is designed to be administered subcutaneously and achieves normal FIX activity levels to prevent bleeding of patients with hemophilia B. Currently approved protein replacement therapy for hemophilia B rely on intravenous injection. With a subcutaneous injection, ISU304 is expected to improve the quality of life and treatment convenience in patients with hemophilia B. The drug is in phase II stage of its clinical trial for the treatment of hemophilia B.

* TU7710: TiumBio

TU7710 is a bypassing agent treatment for patients with neutralizing antibodies and is an innovative drug candidate with a half-life 6~7 times greater than conventional treatments through our transferrin fusion gene recombination technology. TU7710 is expected to dramatically improve the convenience and quality of life of hemophilia patients with neutralizing antibodies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Hemophilia B.

If you're tracking ongoing Hemophilia B Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Hemophilia B Treatment Drugs [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Hemophilia B Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia B with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia B Treatment.
* Hemophilia B Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hemophilia B Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia B market.

Hemophilia B Companies

Shanghai Vitalgen BioPharma, Belief BioMed, TiumBio, Jiangsu Gensciences, Centessa Pharmaceuticals, Takeda, Sanofi, GC Biopharma Corp, Equilibra Bioscience LLC, Regeneron Pharmaceuticals, ISU Abxis and others.

Hemophilia B pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Hemophilia B Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Hemophilia B Pipeline Report covers it all - check it out now @ Hemophilia B Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Hemophilia B Pipeline Report

* Coverage- Global
* Hemophilia B Companies- Shanghai Vitalgen BioPharma, Belief BioMed, TiumBio, Jiangsu Gensciences, Centessa Pharmaceuticals, Takeda, Sanofi, GC Biopharma Corp, Equilibra Bioscience LLC, Regeneron Pharmaceuticals, ISU Abxis and others.
* Hemophilia B Therapies- REGV131, LNP1265, APVO101, SPK-9001, ANB-002, Benefix, IB1001, marstacimab and others.
* Hemophilia B Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hemophilia B Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Hemophilia B Treatment landscape in this detailed analysis @ Hemophilia B Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Hemophilia B: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hemophilia B - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* BBM-H901: Belief Biomed
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ISU304: ISU ABXIS
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* TU7710: TiumBio
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Hemophilia B Key Companies
* Hemophilia B Key Products
* Hemophilia B - Unmet Needs
* Hemophilia B - Market Drivers and Barriers
* Hemophilia B - Future Perspectives and Conclusion
* Hemophilia B Analyst Views
* Hemophilia B Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hemophilia-b-pipeline-drugs-report-2025-exploring-emerging-therapies-and-innovative-drug-developments-across-key-indications]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hemophilia B Pipeline Drugs Report 2025: Exploring Emerging Therapies and Innovative Drug Developments Across Key Indications here

News-ID: 4214600 • Views:

More Releases from ABNewswire

How Gastric Balloon Works: A Complete Guide by Dr. Moein
How Gastric Balloon Works: A Complete Guide by Dr. Moein
The gastric balloon at Healthy Life Bariatrics in Los Angeles offers a non-surgical, temporary solution for patients seeking to lose 15-20% of their body weight when diets haven't worked. Inserted into the stomach under light sedation, the balloon helps you feel full faster and promotes portion control. Under the guidance of Dr. Babak Moein, a double board-certified and fellowship-trained bariatric surgeon, the program prioritizes safety, support, and long-term success through
Restore Confidence & Definition with Arm Lift Surgery in Los Angeles
Restore Confidence & Definition with Arm Lift Surgery in Los Angeles
An arm lift, or brachioplasty, is a surgical procedure performed by Dr. Babak Moein in LA to eliminate excess skin and fat from the upper arms-often caused by weight loss, aging, or genetics. This advanced body contouring procedure tightens underlying tissues and removes sagging skin, helping patients achieve firmer, more defined arms. Dr. Moein, a double fellowship-trained cosmetic surgeon, uses strategic incisions and optional VASER liposuction for natural-looking, long-lasting results. For
Restore That PrePregnancy Confidence with a Mommy Makeover in Los Angeles
Restore That PrePregnancy Confidence with a Mommy Makeover in Los Angeles
A Mommy Makeover at Moein Surgical Arts in Los Angeles is a customized body contouring procedure aimed at restoring your pre-pregnancy figure. This makeover is led by Dr. Babak Moein, a dual board-certified cosmetic and minimally invasive surgeon. The procedure typically includes a tummy tuck, liposuction, and skin tightening, all tailored to meet your individual body and aesthetic goals. Motherhood is a profound journey, but the physical changes it brings can
Turn Back the Clock with a Natural-Looking Facelift in Los Angeles
Turn Back the Clock with a Natural-Looking Facelift in Los Angeles
A facelift at Moein Surgical Arts in Los Angeles offers natural-looking rejuvenation for those seeking to lift sagging skin, redefine the jawline, or smooth deep facial folds. Performed by Dr. Babak Moein-one of the few U.S. surgeons double board-certified in cosmetic and minimally invasive surgery-the procedure targets signs of aging while preserving your facial identity. Aging is a beautiful journey, but it doesn't mean you have to live with sagging skin

All 5 Releases


More Releases for Hemophilia

Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Stren …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts What Is the Expected CAGR for the Hemophilia Market Through 2025? In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR)
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028. During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis. Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748 This latest report researches the industry structure,
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports. Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504 The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes